Systems pharmacology augments drug safety surveillance
暂无分享,去创建一个
[1] Nested Case-control Study , 1992 .
[2] Hyung-Suk Kim,et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration , 1995, Cell.
[3] G. Lambert,et al. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. , 1997, Clinical chemistry.
[4] L. Meskin. Proceed with caution. , 1998, Journal of the American Dental Association.
[5] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[6] T. Branchek,et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. , 1999, European journal of pharmacology.
[7] J. Nordrehaug,et al. Serotonin is associated with coronary artery disease and cardiac events. , 1999, Circulation.
[8] U. Ikeda,et al. Serotonin Increases Interleukin-6 Synthesis in Human Vascular Smooth Muscle Cells , 2000, Circulation.
[9] Peter Libby,et al. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.
[10] R. O’Neill,et al. Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.
[11] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[12] D. Graham,et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study , 2005 .
[13] H. Cottam,et al. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[14] V. Klauss,et al. Selective COX-2 Inhibitors and Risk of Myocardial Infarction , 2005, Journal of Vascular Research.
[15] S. Shoor,et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.
[16] M. Hauben,et al. Data mining for signals in spontaneous reporting databases: proceed with caution , 2007, Pharmacoepidemiology and drug safety.
[17] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[18] Aric Hagberg,et al. Exploring Network Structure, Dynamics, and Function using NetworkX , 2008 .
[19] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[20] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[21] Jesse A Berlin,et al. Adverse event detection in drug development: recommendations and obligations beyond phase 3. , 2008, American journal of public health.
[22] Ravi Iyengar,et al. Network analyses in systems pharmacology , 2009, Bioinform..
[23] A. Bate,et al. Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.
[24] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[25] Seth I. Berger,et al. Systems Pharmacology of Arrhythmias , 2010, Science Signaling.
[26] Trey Ideker,et al. Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..
[27] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[28] Tsippi Iny Stein,et al. In-silico human genomics with GeneCards , 2011, Human Genomics.
[29] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[30] Ben Y. Reis,et al. Predicting Adverse Drug Events Using Pharmacological Network Models , 2011, Science Translational Medicine.
[31] Xing-Ming Zhao,et al. Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..
[32] G. Kouraklis,et al. Correlation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and Retinoid X Receptor-α (RXR-α) expression with clinical risk factors in patients with advanced carotid atherosclerosis , 2011, Medical science monitor : international medical journal of experimental and clinical research.
[33] P Ryan,et al. Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.
[34] E. Braunwald,et al. A tale of coronary artery disease and myocardial infarction. , 2012, The New England journal of medicine.
[35] D. Madigan,et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.
[36] Xing-Ming Zhao,et al. Exploring drug combinations in genetic interaction network , 2012, BMC Bioinformatics.
[37] Zhong Wang,et al. Modular pharmacology: the next paradigm in drug discovery , 2012, Expert opinion on drug discovery.
[38] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[39] Shawn E Simpson. A positive event dependence model for self-controlled case series with applications in postmarketing surveillance. , 2013, Biometrics.
[40] Damian Szklarczyk,et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration , 2012, Nucleic Acids Res..
[41] A. Marks,et al. Calcium cycling proteins and heart failure: mechanisms and therapeutics. , 2013, The Journal of clinical investigation.
[42] N. Tatonetti,et al. Connecting the Dots: Applications of Network Medicine in Pharmacology and Disease , 2013, Clinical pharmacology and therapeutics.
[43] D. Madigan,et al. Medication-Wide Association Studies , 2013, CPT: pharmacometrics & systems pharmacology.
[44] Patrick Aloy,et al. Analysis of chemical and biological features yields mechanistic insights into drug side effects. , 2013, Chemistry & biology.
[45] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[46] J. Hansen,et al. Carotid Atherosclerosis Predicts Future Myocardial Infarction But Not Venous Thromboembolism: The Tromsø Study , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[47] R. Altman,et al. Integrating systems biology sources illuminates drug action , 2014, Clinical pharmacology and therapeutics.
[48] Hisashi Adachi,et al. Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.
[49] Zhongming Zhao,et al. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. , 2014, Journal of the American Medical Informatics Association : JAMIA.
[50] Christopher. Simons,et al. Machine learning with Python , 2017 .